Evotec SE (XSWX:EVT) Shareholder Yield % : 11.74% (As of Mar. 2026)


XSWX:EVT Evotec SE XSWX:EVT
68 GF Score
Price CHF4.50
GF Value CHF6.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Shareholder Yield %?

Evotec SE XSWX:EVT +4.02% 68 Shareholder Yield % is 11.74% as of Mar. 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 969 Drug Manufacturers companies, Evotec SE ranks better than 93.91% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Evotec SE's Shareholder Yield % was 11.74%.


Evotec SE  (XSWX:EVT) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Evotec SE Shareholder Yield % Related Terms


Evotec SE Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Evotec SE's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Shareholder Yield % Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.88 0.39 -2.86 7.13 33.82

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.41 24.12 33.87 33.82 13.43

XSWX:EVT vs ZTS, UTHR, VTRS: Shareholder Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Shareholder Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Evotec SE's Shareholder Yield % falls into.


XSWX:EVT
68GF Score
Evotec SE XSWX:EVT
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Shareholder Yield % Calculation

Evotec SE's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+14.93 %
=14.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 11.74% mean?
Evotec SE (XSWX:EVT) has a Shareholder Yield % of 11.74% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #59 out of 969 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Evotec SE's Shareholder Yield % too high?
Evotec SE's current Shareholder Yield % is 11.74%. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Evotec SE's value of 11.74% is 3352.9% above this industry median. Based on the distribution chart, Evotec SE ranks #59 out of 969 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #59 out of 969 companies for Shareholder Yield %. This places Evotec SE in the top 6% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.34. Evotec SE's value of 11.74% is 3352.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Shareholder Yield % of 11.74% is 3352.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Shareholder Yield % is 11.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Shareholder Yield % is 11.74% and 3352.9% above the Drug Manufacturers industry median of 0.34. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Shareholder Yield % is 11.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for XSWX:EVT:

  • Shareholder Yield %: 11.74%
  • GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs
  • Industry Position: 3352.9% above the Drug Manufacturers median (#59 of 969)

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score

Get the complete analysis for XSWX:EVT

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.50
Price
CHF6.99
GF Value